Add news
News Every Day |

First new treatment for asthma and COPD in half a century – new study

Every 30 seconds, someone in the world will experience a flare-up of their asthma or chronic obstructive pulmonary disease (COPD) symptoms. For decades, the standard treatment for these potentially life-threatening episodes has remained unchanged – treatment with steroids, such as prednisolone.

Unfortunately, these drugs don’t work for everyone and they have significant levels of serious side-effects. Nearly one-third of patients treated with steroids will see their symptoms worsen again within a month, requiring more treatment and increasing the risk of side-effects.

But what if there was a better option?

Our latest study, published in The Lancet Respiratory Medicine, has revealed that a drug called benralizumab – administered as an injection – may be the breakthrough that we have been waiting for. The results suggest that this treatment, administered at the time of a flare-up, is highly effective and spares patients the side-effects of steroids.

Inflammation caused by a type of white blood cell called eosinophils is a key driver of flare-ups in many people with asthma and some people with COPD. Eosinophilic inflammation plays a role in at least half of asthma and one-third of COPD flare-ups. For these people, targeting eosinophils when symptoms worsen is a promising strategy.

Benralizumab, a monoclonal antibody, is already used for the long-term management of eosinophilic asthma, with studies still evaluating the effect for long-term management in eosinophilic COPD. However, the potential to manage critical moments, when symptoms suddenly worsen, had not been studied before.

In the trial, 158 patients experiencing asthma or COPD flare-ups were recruited from two UK hospitals. Participants were randomly assigned to one of three groups: standard treatment with prednisolone tablets, a single injection of benralizumab alone, or a combination of the two.

Corticosteroids come with a lot of side-effects, including some serious ones. Sonis Photography/Shutterstock

Striking results

The main outcome we were interested in was the “rate of treatment failure”, defined as the need for further therapy, hospitalisation or death, within 90 days.

The results were striking: 74% of those treated with prednisolone alone experienced treatment failure within 90 days. Failure rates dropped to 47% with benralizumab alone and 42% with the combination therapy.

Pooled data from the benralizumab-treated groups showed that only 45% of patients experienced treatment failure, compared with 74% in the prednisolone group. For every four patients treated with benralizumab, one treatment failure was prevented.

The benefits of benralizumab extended beyond treatment failure rates. Patients treated with benralizumab reported faster symptom recovery and improved quality of life. For example, patients were able to breathe better and had less discomfort.

Benralizumab also had a better safety profile compared with prednisolone. Side-effects commonly linked to prednisolone, such as high blood sugar, were absent in patients who received benralizumab alone.

This makes the therapy especially promising for people who face significant risks from repeated prednisolone use, such as older adults and those with diabetes or osteoporosis.

While a lower dose of benralizumab is already approved for long-term asthma management, it is not yet licensed for use during flare-ups at the dose used in this study. For that to happen, phase 3 trials will be needed, involving more diverse and international populations. (Phase 3 is the final phase of testing in humans before a drug is approved.)

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations of asthma and COPD in over 50 years.

In the time it has taken you to read this article, 40 people in the world have experienced an eosinophilic asthma or COPD flare-up. Under current best treatments, 30 of them will require further care within 90 days. Benralizumab offers the potential to break this cycle of recurrent treatment and side-effects, transforming the way we manage these common and debilitating conditions.

Could this drug be the breakthrough we’ve been waiting for? The early evidence suggests it just might be.

Mona Bafadhel receives funding from the National Institute of Health Research, Asthma+Lung UK, and Horizon Europe. For this study, Mona Bafadhel received funding from AstraZeneca to complete the study described in this report. The funder (AstraZeneca) was not involved in the study design, data collection, data analysis, data interpretation or decision to submit to publish.

Richard Russell has received personal grants for Consultations with AstraZeneca Ltd.

Sanjay Ramakrishnan receives funding from the National Institute for Health and Care Research (NIHR) and The Charlie's Research Foundation. Sanjay Ramakrishnan's institution received funding from AstraZeneca to conduct the study reported in the article.

Москва

Бадминтонист из Бердска стал одним из лучших в стране

Реклама
Top 6 nutrition questions men should ask themselves after 40

To maintain health and remain full of energy, men will be helped by this

Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market

Here’s more of what you’ll see through Meta’s $1,000 smart glasses

Tesla shares sink as deliveries miss forecasts by 'wide margin': report

Hyundai’s Insteroid is an EV one-off for gamers

Ria.city
Реклама
  • ИП Попов А.П.
  • ИНН: 602715631406
Ревматолог: "3 апреля 2024 в г.Вашингтон запущена квота"

Каждый человек с больными суставами имеет право получить...






Реклама
  • ИП Попов А.П.
  • ИНН: 602715631406
Ревматолог: "3 апреля 2024 в г.Вашингтон запущена квота"

Каждый человек с больными суставами имеет право получить...


Реклама
  • ИП Попов А.П.
  • ИНН: 602715631406
Ревматолог: "3 апреля 2024 в г.Вашингтон запущена квота"

Каждый человек с больными суставами имеет право получить...

Read also

Cikakken Tarihin Rabiu Rikadawa: Fitaccen Jarumin Kannywood da Nollywood » Labaran Yau

Cowboys acquire quarterback Joe Milton from Patriots in trade: reports

NBA scouts compare Cooper Flagg to Jayson Tatum, Scottie Pippen, Kawhi Leonard

News, articles, comments, with a minute-by-minute update, now on Today24.pro

News Every Day

Hyundai’s Insteroid is an EV one-off for gamers

Today24.pro — latest news 24/7. You can add your news instantly now — here


News Every Day

Tesla shares sink as deliveries miss forecasts by 'wide margin': report



Sports today


Новости тенниса
ATP

Медведев вылетел из топ-10 рейтинга ATP, Рублёв стал первой ракеткой России



Спорт в России и мире
Москва

Росгвардейцы обеспечили безопасность матча ВХЛ в Челябинске



All sports news today





Sports in Russia today

Москва

Бадминтонист из Бердска стал одним из лучших в стране


Новости России

Game News

Call of Duty will finally let console players turn off crossplay to dodge PC cheaters, which is potentially terrible news for all the legit PC players


Реклама
Top 6 nutrition questions men should ask themselves after 40

To maintain health and remain full of energy, men will be helped by this

Реклама
Top 6 nutrition questions men should ask themselves after 40

To maintain health and remain full of energy, men will be helped by this

Реклама
The most beautiful beach towns with cheap living

A huge number of people around the world dream of one day breaking out of the daily routine

Russian.city

Реклама
The most beautiful beach towns with cheap living

A huge number of people around the world dream of one day breaking out of the daily routine


Сергей Собянин

Собянин: в 2025–2026 годах завершится реконструкция семи вокзалов


Губернаторы России
Алексей Сёмин

Компания enKod на Global Tech Forum: как технологии меняют маркетинг


Рейтинг пяти лучших маркетинговых агентств: VICTORY GROUP занял первое место

Никоненко заявил об отказе играть с Михаилом Ефремовым, выходящим по УДО

«Ассоциация Блогеров и Агентств» и «Рейтинг Рунета» выпускают первый в России рейтинг агентств с экспертизой в инфлюенс-маркетинге

Ранняя весна оживила клещей в парках Москвы 


Органный концерт «340 лет Баху и Генделю» в Москве: Владимир Скоморохов представит барочные шедевры

«Жаль, что сегодня не 1 апреля»: Егор Крид прокомментировал ДТП с участием его машины

Рэпер Птаха назвал Иудой поддерживающего ВСУ Noize MC

Жена Джигана рассказала, что их дети перенесли тяжелые болезни за три месяца


Ямаль — в Химках, Черчесов вернулся в Казахстан, Синнеру продлили бан, чемпионат Гренады — на российских экранах

WTA сменила флаг теннисистки Дарьи Касаткиной на австралийский

Касаткина рассказала, почему перешла под флаг Австралии

«Это привилегия». Елена Рыбакина высказалась о том, что представляет Казахстан


Реклама
Top 6 nutrition questions men should ask themselves after 40

To maintain health and remain full of energy, men will be helped by this


MD Facility Management: в начале 2025 года до 80% затрат на обслуживание ТЦ приходилось на фонд оплаты труда

Минск, Москва, Нижний Новгород, Казань, Ульяновск и Волгоград приняли литературный десант

Калмыкия готова к проведению первого этапа Кубка России по ралли-рейду «Дикий тюльпан»

Александр Буйнов приглашает на свой 75-летний юбилей


MD Facility Management: в начале 2025 года до 80% затрат на обслуживание ТЦ приходилось на фонд оплаты труда

В аэропорту Шереметьево с апреля вырастут штрафы

Паллиативная помощь в Подмосковье: 250 участников обучились в 37 школах

В Москве задержали фейкового водителя Владимира Путина на Aurus Senat


Лидер Буркина-Фасо Ибрагим Траоре приедет в Россию на празднование Дня Победы

Агрессивный медведь изодрал мужчину на делянке в Подмосковье

Игрушки, хозтовары и рекламная продукция стали самыми доставляемыми товарами в торговые сети в 2024 году – «Деловые Линии»

Toyota Camry в кузове XV40 за 3,7 млн: в Москве предлагают экземпляр с пробегом 10 тысяч км


Реклама
The most beautiful beach towns with cheap living

A huge number of people around the world dream of one day breaking out of the daily routine


Путин в России и мире
Реклама
The most beautiful beach towns with cheap living

A huge number of people around the world dream of one day breaking out of the daily routine



Реклама
The most beautiful beach towns with cheap living

A huge number of people around the world dream of one day breaking out of the daily routine



Реклама
Top 6 nutrition questions men should ask themselves after 40

To maintain health and remain full of energy, men will be helped by this



Реклама
The most beautiful beach towns with cheap living

A huge number of people around the world dream of one day breaking out of the daily routine

Персональные новости Russian.city
Тимати

В Перми 1 апреля откроется кофейня Тимати Stars Coffee



News Every Day

T-Mobile closes Lumos deal after dropping DEI




Friends of Today24

Музыкальные новости

Персональные новости